AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

This study is a first-in-human, open-label, nonrandomized, single center Phase 1 dose-escalation study to assess the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity of AB821 monotherapy given every 2 weeks (Q2W) or every 3 weeks (Q3W) in participants with recurrent locally advanced or metastatic melanoma and other immune-responsive solid tumors. Immune-responsive solid tumors are defined as those for which immune checkpoint inhibitors form part of the standard-of-care therapy.

Trial Details

NCT ID
NCT07027488
Phase
PHASE1
Sponsor
Yale University
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • AB821
Locations (sample)
  • New Haven, Connecticut, United States|41.30815,-72.92816

Key Eligibility Criteria

  • ≥18 years at the time consent is signed.
  • Ability to provide written informed consent for the study.
  • ECOG PS of 0 or 1.
  • Participants of childbearing potential must not be pregnant at enrollment and agree to comply with contraception requirements. Participants with pa…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →